DaVita (DVA) vs Viemed Healthcare (VMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Viemed Healthcare (VMD) has outperformed DaVita (DVA) over the past year, gaining 36.4% versus a gain of 34.9%. Over five years, VMD leads with a +62.4% price change compared with +57.5% for DVA. DaVita is the larger company by market cap ($11.28 billion vs $356.9 million), about 31.6 times the size.
On valuation, DaVita trades at a lower forward P/E (10.3x vs 23.4x for Viemed Healthcare).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DVA | VMD |
|---|---|---|
| Share price | $176.78 | $9.37 |
| Market cap | $11.28B | $356.89M |
| 1-day change | -2.01% | +0.43% |
| YTD return | +55.60% | +26.11% |
| 1-year return | +34.91% | +36.39% |
| 5-year return | +57.54% | +62.39% |
| P/E ratio (TTM) | 14.93 | 26.03 |
| Forward P/E | 10.31 | 23.43 |
| EPS (TTM) | $11.84 | $0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.64B | — |
| Revenue growth (YoY) | +6.46% | — |
| Net income (latest FY) | $746.80M | — |
| Operating margin | 14.98% | — |
| Net margin | 5.47% | — |
| 52-week high | $247.49 | $12.61 |
| 52-week low | $101.00 | $6.05 |
| Distance from 52-week high | -28.57% | -25.69% |
| Analyst consensus | buy | — |
| Avg. price target upside | +24.37% | — |
| Average volume | 776.03K | 353.23K |
| Shares outstanding | 63.80M | 38.09M |
| Employees | 78,000 | — |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 31.6 times larger than Viemed Healthcare by market value ($11.28B vs $356.89M).
- Viemed Healthcare trades at a higher earnings multiple (26.0x vs 14.9x trailing P/E).
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
DVA vs VMD FAQ
Which is bigger, DaVita or Viemed Healthcare?
DaVita (DVA) is larger, with a market capitalization of $11.28B compared with $356.89M for Viemed Healthcare (VMD).
Which stock has performed better over the past year, DVA or VMD?
VMD returned +36.39% over the past 12 months, compared with +34.91% for DVA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DVA or VMD?
DVA has the lower trailing P/E at 14.9, versus 26.0 for VMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DaVita and Viemed Healthcare in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.